chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This case was extracted from the VAERS database via QSCAN on 11 March 2009 (reference number 247279). A 30-year-old male patient received an intramuscular injection of FLUZONE SV 2005-2006 (lot number U1846AA) on 10 November 2005. He experienced a generalized vaso-vagal response, was given orange juice, and returned to work. Approximately 45 minutes later, he presented to the emergency room or doctor complaining of a persistent dry cough, scratchy throat with puffiness, and tearing and itching of eyes. The events recovered.
15 minute period of staring, decreased responsiveness, and shivering and jerking movements, with fever to 102, occurring 3 hrs after vaccines given. Recovered abruptly, except for fever.
Completed vaccine series on 2/6/21, started having symptoms 3/30/21, tested positive for covid on 3/31/21. Had known household exposure (child).
Started having TIA?s not sure if related but seems suspect when I have never had anything like that before the vaccine
p/vax pt devel cellulitis characterized by red; painful; swollen area at inj site; seen by MD & tx ATB
Body Aches, Nausea, Vomiting, Temp> 100F
Pfizer BioNTech COVID-19 EUA All over intermediate bone/muscle aches, headache, nausea, vomiting, low fever
Had shot 11/7/03. 11/08/03 AM noted itching, swelling, redness at injection site LUE. Seen by nurse 11/10/03. No induration noted, redness at site measures 6 cm, area warm to touch, itching, redness reported.
There was no immediate reaction to the vaccine.  Due to my autoimmune issue, I already experience fatigue.  About two months after the vaccine, many of my autoimmune issues suddenly worsened.  Before the vaccine, on occasion, I would need a one-hour nap.  Now, my dry eye and dry mouth issues are much worse and at least five days a week, I must take a two-four hour nap in order to function for a few more hours.  I am unable to function well after 4pm, regardless of nap length.  It did not occur to me it was the vaccine until my dermatologist told me her autoimmune issues flared up after she was vaccinated.  I am now a year in, and the exhaustion has not abated.  I had a Moderna booster on 12/1/21.
Nausea; This spontaneous case was reported by a consumer and describes the occurrence of NAUSEA (Nausea) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 11-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Jan-2021, the patient experienced NAUSEA (Nausea). At the time of the report, NAUSEA (Nausea) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications reported by investigator o No treatment medications provided by the reporter.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
Pt recvd vax 12AUG92 & exp fainting w/in 24 hrs pt had recovered; No furthere details were provided;
Premedicated w Zyrtec Fri & Sat mornings since had similar reaction to Pfizer in Jan 21 took 30 mg & 25mg at time of shot Took Zyrtec Sun not any Monday - tongue started swelling at 3pm Mon Took Benadryl 50mg q 4 hrs thru Thurs afternoon (25 50 mg)
PT WAS SEATED, WAITING FOR 15 MINUTE MONITORING PERIOD POST VACCINE ADMINISTRATION. FELT DIZZY. REMAINED SEATED BUT PASSED OUT FOR A FEW SECONDS. CALLED 911. CAME TO, WAS ABLE TO TALK AND BREATHE BUT WAS SWEATY AND DIZZY AND PALE. SAT ON FLOOR SO HE WOULDN'T SLIDE OFF CHAIR IN CASE HAPPENED AGAIN. PARAMEDICS CAME, MONITORED BP, BLOOD SUGAR, EKG. HE HAD LOW BP BUT IT CAME BACK TO NORMAL IN FEW MINUTES. PARAMEDICS DETERMINED HE WAS OK TO GO HOME, DIDN'T NEED TO GO TO HOSPITAL
presented to ED with decrease in appetite, nausea, vomiting x approximately 1 wk; tested positive for COVID; fever and fatigue, decreased oxygen saturation; intubated on 8/7/21; condition worsened where she passed away at the hospital
body aches; chills; low grade fever; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (body aches), CHILLS (chills) and PYREXIA (low grade fever) in a 35-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 002A21A and 025J20-2A) for COVID-19 vaccination.     No Medical History information was reported.   On 27-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 24-Feb-2021, the patient experienced MYALGIA (body aches), CHILLS (chills) and PYREXIA (low grade fever). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. On 25-Feb-2021, MYALGIA (body aches), CHILLS (chills) and PYREXIA (low grade fever) had resolved.            No relevant concomitant medications were provided. The action taken for mRNA-1273 was not applicable.
Tightness in chest and weakness and numbness in right side.  Symptoms occurred about 15 minutes after injection.
Pt recvd 1st dose of Hep B vax on 5FEB92 & exp stinging pain @ the site of inject;
About six hours after receiving the injection, the following symptoms, very similar to the "flu" occurred: Body aches, headache, upset stomach, slight fever, fatigue. Lasting overnight and half of the next day. Also, there was/is soreness at the injection site.
This spontaneous report was received from a pharmacist refers to a 51 year old female patient. On 21-JAN-2014, the patient was vaccinated with ZOSTAVAX Lot No: J011213 (Expiry: 14-NOV-2014) dose 1, subcutaneous. On an unknown date in January 2014, the patient experienced cold sore on her lip. The patient sought medical attention and called the pharmacy. The patient was prescribed with VALTREX. The outcome of the event cold sore on her lip was reported as recovering. This case was linked to the case 1401USA014220 (same reporter link). Additional information is not expected.
pt devel reactive ITP-which required tx w/pred; when a CBC was run on 8/10/99 platelet count was 1000;pt still on pred;
Dose administered to patient after improper storage and handling/Patient was given vaccine that had been thawed, re-frozen and thawed again; This spontaneous case was reported by a nurse and describes the occurrence of PRODUCT STORAGE ERROR (Dose administered to patient after improper storage and handling/Patient was given vaccine that had been thawed, re-frozen and thawed again) in a 36-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 002C21A) for COVID-19 vaccination.     Concurrent medical conditions included Pain. Concomitant products included PARACETAMOL (TYLENOL) from 15-Aug-2021 to an unknown date for Pain.    On 26-Aug-2021 at 10:00 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-Aug-2021, the patient experienced PRODUCT STORAGE ERROR (Dose administered to patient after improper storage and handling/Patient was given vaccine that had been thawed, re-frozen and thawed again). On 26-Aug-2021, PRODUCT STORAGE ERROR (Dose administered to patient after improper storage and handling/Patient was given vaccine that had been thawed, re-frozen and thawed again) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No treatment medication was provided.  It was reported that no adverse event occurred.  The patient race was Black.   Most recent FOLLOW-UP information incorporated above includes: On 01-Sep-2021: Follow up received: patient details, concomitant medication, time and route of administration for first dose of vaccine was updated.
This spontaneous report was received from a nurse concerning a patient of unknown age and gender. There was no information about the patient's concurrent conditions, medical history or concomitant medication. On 20-MAR-2018, the patient was vaccinated with VAQTA lot # M022531 with expiration date of 23-FEB-2018, for prophylaxis (dose, route of administration, lot number and expiration date were not reported). No adverse effects were reported.
High fever (103 when I was finally coherent enough to take it). Aunts who were staying with me at the time were unable to wake me and were frantically trying to get me to agree to go to the hospital, they were from several states away so didn't know where the local hospital was and I wasn't coherent enough to tell them. This was terrifying for them and me. Once I was coherent again the next day, I took aspirin for the fever (I am allergic to Tylenol).
Moderna Covid-19 vaccine administered after 30-day Use By Date; Moderna Covid-19 vaccine administered after 30-day Use By Date; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Moderna Covid-19 vaccine administered after 30-day Use By Date) and PRODUCT STORAGE ERROR (Moderna Covid-19 vaccine administered after 30-day Use By Date) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 058H21A) for COVID-19 vaccination.     No Medical History information was reported.   On 25-Feb-2022, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to .25 milliliter. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 25-Feb-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Moderna Covid-19 vaccine administered after 30-day Use By Date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Moderna Covid-19 vaccine administered after 30-day Use By Date). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Moderna Covid-19 vaccine administered after 30-day Use By Date) and PRODUCT STORAGE ERROR (Moderna Covid-19 vaccine administered after 30-day Use By Date) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The patient was not taking any concomitant medication.  It had been stated that administered to four patients in their deltoid muscle. It had been stated that paitent were not allergies and also did not tested positive for Covid-19. Paitent did not received any other vaccine within one month prior to Moderna and at the time of the vaccination and also did not had any acute or chronic illnesses. . Also did not provide any information about the First and the Second dose of the vaccine. The patient did not receive a third dose of the Moderna Covid-19 vaccine and they did not experienced any symptoms.  Date the vial was initially stored in the refrigerator was 18-Jan-2022.  No Treatment medication reported   Most recent FOLLOW-UP information incorporated above includes: On 01-Mar-2022: Reporter contact information was updated.
Systemic: Allergic: Difficulty Swallowing, Throat Tightness-Mild, Additional Details: patient left store approximately 30 minutes after administration of benedryl denying feeling of throat sweeling for approximately 20 minutes. Pt and husband advised to go to nearest ER if sysmptoms reoccured or additional symptoms appeareded.. Follow up call made to patient at 1630, pt stated she is \"feeling much better\". Advised patient to talk to dr for ok on 2nd dose and to make admisistrator of second dose, if applicable, aware of first reaction.
nausea; vomiting; headache; feeling feverish (no fever); Feeling beat up; dizziness; fatigue; This is a spontaneous report from a contactable consumer (patient). A 48-year-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE; Lot number: EL3247), via an unspecified route of administration in the left arm, on 05Feb2021 at 11:45 (at the age of 48-years-old) at a single dose for COVID-19 immunisation. Medical history included multiple sclerosis. The patient was not pregnant at the time of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications, taken within two weeks of vaccination, included fingolimod hydrochloride (GILENYA), baclofen (MANUFACTURER UNKNOWN), mirabegron (MYRBETRIQ), bupropion hydrochloride (WELLBUTRIN), and hydroxyzine hydrochloride (HYDROXIN). The patient previously took acetylsalicylic acid (ASPIRIN) and experienced allergies and ibuprofen (MANUFACTURER UNKNOWN) and experienced allergies. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient experienced dizziness and fatigue on 05Feb2021 and nausea, vomiting, headache, feeling feverish (no fever), and feeling beat up on 06Feb2021 at 13:30. The events were reported as non-serious. The clinical course was reported as follows: Within one to two hours (as reported), on and off, the patient felt dizziness and fatigue. After 26 hours (as reported), the patient felt nausea, vomiting, headache, fatigue, feeling feverish (no fever) and feeling beat up. The feeling beat up lasted 12-14 hours and the headache lasted 2 days. The patient did not receive any treatment for the events. The clinical outcome of dizziness, fatigue, nausea, vomiting, and feeling feverish (no fever) was recovered on an unspecified date, feeling beat up was recovered on 07Feb2021, and headache was recovered on 08Feb2021. It was also reported that since the vaccination, the patient had not been tested for COVID-19.
Patient broke out in hives after 36 hr of being vaccinated. He started taking BENADRYL every 6 hrs to relieve symptoms. After BENADRYL wears off hives would return and itch.
This is a spontaneous report from a contactable healthcare professional  (HCP) and from a contactable other-HCP (Medical Assistant) on behalf of another Other-HCP. The other-HCP reported similar events for 7 patients. This report is 5th of 7 patients. A 4-month-old male patient received PREVNAR 13 (Batch/Lot # W11304, Expiry date 31May2020) intramuscularly at the left thigh, on 10Oct2018, 01:09, at 0.5 ml single dose on an unspecified date for immunization at a clinic. The patient had no medical history. Concomitant medications included first doses of diphtheria vaccine toxoid, hepatitis b vaccine, pertussis vaccine acellular, tetanus vaccine toxoid (DTAP HEPB, lot number: H994T), hib vaccine (HIB, lot number: U1916AAA), and polio vaccine (POLIO); all intramuscular, on 10Oct2018, at single dose at the right thigh for immunization. Other concomitant medications included hydrocortisone 2.5% and nystatin; both on 10Oct2018 as a topical cream. On an unspecified date the patient received the vaccine after a temperature excursion occurred. On an unspecified date the vaccine was stored at 57 degrees Fahrenheit for approximately 4 hours. It was also reported that the patient experienced candidal dermatitis and infantile eczema on 10Oct2018. The patient recovered from the events, candidal dermatitis and infantile eczema on the same day of 10Oct2018. Follow-up (02Jan2019): New information from a contactable healthcare professional included: reporter details, patient details, suspect drug details, concomitant medication details and course of events. Follow-up (20Feb2019): New information from a contactable healthcare professional includes: new events (candidal dermatitis and infantile eczema), age of vaccination, route of vaccination, dose, administration date, time of vaccination, and anatomical location of the suspected vaccine, lot number for the concomitant vaccine, DTAP HEPB and HIB was updated (from H99HT and U196AAA), event onset of drug maladministration, and additional concomitant medications.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2018416194 different patient, same reporter/drug/event.
None  Administration error - patient was given 1 ml of Moderna rather than 0.5 ml
Patient came in with his family of 4 people. All of them signed up for a covid booster and flu shot, except for him. There was a language barrier and we did not realize that he didn't want to receive the updated covid booster. He received the booster and did not request the vaccine
2 vaccines in (L) leg on 5/4/12. Mom calls & comes in on 5/7/12; child c/o it hurts. Red & warm to touch with some swelling & itching. Temp - 98.0.
About 48 hours after my bivalent booster, I was preparing to see a patient in my role as a doctor. I was reading one of my prior notes. It was a printout. I experienced and ocular migraine which is precedented for me although I have not had one in a very long time. It lasted only 5 or 10 minutes. I was pushing myself to prepare myself for the patient. I was past the ocular migraine disturbance. I noticed I could not read for comprehension. The words looked more like designs than words. The words did not mean anything to me as I would normally recognize them. I recognized COVID that was written on the note, but I was unable to read and understand it. In about 10 minutes it had resolved. I continued seeing my patients. That evening about 6:00pm I went to another physician I know and explained that I had something like a TIA transient ischemic attack. I was encouraged to go to the ER and have some tests run. I was seen my several physicians and sent home that night. I was in the ER for about four or five hours and given mandatory follow ups for further study. I was without symptoms after the first 10 minutes and have not had another episode like that as of today. The only symptoms I've had like that since that day have been very mild abnormal nerve vibrations in my leg. I have upcoming neurologist appointment.
Patient came to recieve the first primary series vaccine and was administered the bivalent booster instead.
possibility of blood clot; metal taste; rash around neck and hands; increase joint pain; Headaches; This is a spontaneous report received from a contactable reporter(s) (Other HCP). The reporter is the patient.  A 67 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), intramuscular, administered in arm right, administration date Dec2021 (Lot number: FH 80n8) at the age of 67 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "thyroid low" (unspecified if ongoing); "Known allergy: Penicillin" (unspecified if ongoing); "Known allergy: skin care products with propylene glycol" (unspecified if ongoing); "Covid", start date: Dec2020, stop date: Dec2020, notes: if covid prior vaccination= Yes, COVID last Dec2020. Concomitant medication(s) included: SYNTHROID. The following information was reported: THROMBOSIS (medically significant) with onset Dec2021, outcome "recovered", described as "possibility of blood clot"; DYSGEUSIA (non-serious) with onset Dec2021, outcome "recovered", described as "metal taste"; RASH (non-serious) with onset Dec2021, outcome "recovered", described as "rash around neck and hands"; ARTHRALGIA (non-serious) with onset Dec2021, outcome "recovered", described as "increase joint pain"; HEADACHE (non-serious) with onset Dec2021, outcome "recovered", described as "Headaches". Therapeutic measures were not taken as a result of thrombosis, dysgeusia, rash, arthralgia, headache. Patient was not tested for covid post vaccination.  No follow-up attempts are possible. No further information is expected.; Sender's Comments: Based on the information provided, a causal association between reported events thrombosis, dysgeusia, rash, arthralgia, headache and the suspect BNT162B2 cannot be excluded. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.
Patient reported when Tdap was administered a "nerve shock" was felt in arm at time injection went into arm-moved up/down arm. Then intermittently continued based on arm position and putting elbow on arm rests. Patient stated this has continued since then-reports this in painful-more than sutures that were placed in finger.
In December 2021, I started having symptoms of colitis, but it was pretty mild. I contracted COVID in January 2022 and started to experience acute and persistent colitis for the next six weeks. At this point, I was under the care of a gastroenterologist, and I was diagnosed with lymphocytic colitis and the biopsy showed acute and chronic inflammation.  I started to experience muscle pains in my legs as well. I am still currently experiencing colitis and the muscle pains. Starting in August, I have been experiencing persistent muscle pain, acute gastritis and colitis. I have an upper GI scheduled tomorrow to see if they can provide some answers about my stomach.
Patient started having severe soreness in left arm, radiating from shoulder through wrist. This started the morning after administration and is persisting 5 days post-administration, however it is starting to lessen. He states that he was unable to lift his arm because the soreness has been so severe. The pain has also impacted his sleep.
This spontaneous report as received from a healthcare worker refers to an unspecified number of patients of unknown age and gender. There was no information about concomitant medications, pertinent medical history, drug and allergies provided. On an unknown date, an unspecified number of patients were vaccinated with unspecified doses of GARDASIL (lots#, expiration dates, doses, frequency, indication, sites and routes of vaccination were not reported) or GARDASIL 9 (lot#, expiration dates, doses, frequency, indication, sites and routes of vaccination were not reported). It was not specified by the reporter, which one of the vaccines the patients received. Subsequently, on an unspecified time after receiving the GARDASIL or GARDASIL 9 the patients "passed out". The outcome of the event was unknown. The relatedness between the event and GARDASIL or GARDASIL 9 was not reported. This is one of several reports received from the same reporter. Additional information has been requested.
Initial unsolicited pregnancy report received from a non-health care professional on 03-MAR-2017. This case involves a 28 years old female patient who was vaccinated intramuscularly with an unknown dose of ADACEL (batch number: U5604AA expiry date: 17-MAR-2019, dose, dose in series were not reported) in the right deltoid on 02-MAR-2017 while she was pregnant. The patient's last menstrual period and estimated conception period was not reported and expected delivery date was reported on 16-MAY-2017. Patient's medical history as pre-existing physician diagnosed allergies, birth defects, medical conditions (specify) was reported as patient is pregnant and Illness at the time of vaccination was reported as reporter denied. Any other vaccinations within four weeks of vaccinations were also reported as unknown. The patient had not reported any medical history and comment regarding the mother's health during pregnancy, specific risk factors (e.g.: alcohol, tobacco drugs) was reported none per reporter. The patient had not reported any concomitant medications. On 03-MAR-2017, one day following the vaccination, the patient had developed pain and limited movement of right arm and exposure during pregnancy. The patient did not reported emergency room (ER) or doctor visit. The event outcome was reported as unknown. List of documents held by sender: none.